Novartis to Acquire Allergy-Drug Developer Excellergy for Up to $2 Billion

Pharmaceutical giant Novartis has announced its intention to purchase Excellergy, a developer of allergy drugs, in a deal valued at up to $2 billion, expanding its portfolio in the allergy treatment market.